{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.38","upperLimit":"5.78","value":"2.61"},{"groupId":"OG001","lowerLimit":"1.41","upperLimit":"9.82","value":"2.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"<1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.51","upperLimit":"4.21","value":"2.89"},{"groupId":"OG001","lowerLimit":"1.38","upperLimit":"5.65","value":"2.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"PD-L1: ≥ 1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"2.76","value":"2.37"},{"groupId":"OG001","lowerLimit":"1.41","upperLimit":"5.65","value":"2.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"PD-L1: < 25%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.71","upperLimit":"16.59","value":"5.75"},{"comment":"Insufficient number of events to calculate upper limit number.","groupId":"OG001","lowerLimit":"1.38","upperLimit":"NA","value":"2.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"PD-L1: ≥ 25%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"2.89","value":"2.55"},{"groupId":"OG001","lowerLimit":"1.41","upperLimit":"5.65","value":"2.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"PD-L1: <50%"},{"categories":[{"measurements":[{"comment":"Insufficient number of events to calculate upper limit number.","groupId":"OG000","lowerLimit":"2.79","upperLimit":"NA","value":"4.21"},{"comment":"Insufficient number of events to calculate upper limit number.","groupId":"OG001","lowerLimit":"1.38","upperLimit":"NA","value":"2.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"PD-L1: > 50%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"2.86","value":"1.51"},{"groupId":"OG001","lowerLimit":"1.28","upperLimit":"8.28","value":"3.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"PD-L1: 1 - < 25%"},{"categories":[{"measurements":[{"comment":"Insufficient number of events to calculate upper limit number.","groupId":"OG000","lowerLimit":"1.51","upperLimit":"NA","value":"6.47"},{"groupId":"OG001","lowerLimit":"1.28","upperLimit":"49.84","value":"13.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Without quantifiable PD-L1 expression at baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"The time from randomization to the date of first documented disease progression, or death due to any cause, whichever occurs first.\n\nTumor PD-L1 expression was defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC assay\n\nProgressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) who are platinum naive or have recurred 6 months or more after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A - Platinum Eligible Subgroup"},{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) who are platinum naive or have recurred 6 months or more after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B - Platinum Eligible Subgroup"}],"paramType":"MEDIAN","populationDescription":"Platinum eligible subgroup","reportingStatus":"POSTED","timeFrame":"From randomization to disease progression or death. Approximately 63 Months","title":"Progression Free Survival (PFS) - Platinum Eligible Subgroup Based on PD-L1 Status","type":"SECONDARY","unitOfMeasure":"Months"}